The treatment of tuberculosis has been complicated by the development of M. tuberculosis strains that are resistant to many, if not all, of the first-line drugs used to combat this infection. This has resulted in the increased use of second-line drugs in treatment regimens. As this reliance on second-line drugs grows, the development of M. tuberculosis strains that are resistant to these drugs will become increasingly problematic. Furthermore, many of these second-line drugs have unwanted complications, such as side- effects and means of delivery into the patient, that minimize their use. Since it has been more than 30 years since a new antibiotic to treat M. tuberculosis infections has been introduced into clinical use, it is of paramount importance that new methods for antituberculosis drug development be investigated. The tuberactinomycins are essential second-line drugs for the treatment of multidrug-resistant tuberculosis, but their wide-spread is limited due to unwanted side-effectsand the need for intramuscular injection during treatment of a patient. This proposal focuses on the discovery of new tuberactinomycin derivatives that have reduced side-effects, have more drug-like charateristics, and have activity against resistant strains. This will be accomplished by combining genetic and molecular engineering of the tuberactinomycin biosynthetic pathways, along with semi-synthetic chemistry.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-DDR-N (01))
Program Officer
Lacourciere, Karen A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Earth Sciences/Natur
United States
Zip Code
Park, Hyunjun; Kevany, Brian M; Dyer, David H et al. (2014) A polyketide synthase acyltransferase domain structure suggests a recognition mechanism for its hydroxymalonyl-acyl carrier protein substrate. PLoS One 9:e110965
McMahon, Matthew D; Rush, Jason S; Thomas, Michael G (2012) Analyses of MbtB, MbtE, and MbtF suggest revisions to the mycobactin biosynthesis pathway in Mycobacterium tuberculosis. J Bacteriol 194:2809-18
Felnagle, Elizabeth A; Podevels, Angela M; Barkei, John J et al. (2011) Mechanistically distinct nonribosomal peptide synthetases assemble the structurally related antibiotics viomycin and capreomycin. Chembiochem 12:1859-67
Felnagle, Elizabeth A; Barkei, John J; Park, Hyunjun et al. (2010) MbtH-like proteins as integral components of bacterial nonribosomal peptide synthetases. Biochemistry 49:8815-7
Park, Hyunjun; Thomas, Michael G (2010) Using surrogates to bypass missing catalytic components. Chem Biol 17:1045-6
Chan, Yolande A; Thomas, Michael G (2010) Recognition of (2S)-aminomalonyl-acyl carrier protein (ACP) and (2R)-hydroxymalonyl-ACP by acyltransferases in zwittermicin A biosynthesis. Biochemistry 49:3667-77
Helmetag, Verena; Samel, Stefan A; Thomas, Michael G et al. (2009) Structural basis for the erythro-stereospecificity of the L-arginine oxygenase VioC in viomycin biosynthesis. FEBS J 276:3669-82
Barkei, John J; Kevany, Brian M; Felnagle, Elizabeth A et al. (2009) Investigations into viomycin biosynthesis by using heterologous production in Streptomyces lividans. Chembiochem 10:366-76
Chan, Yolande A; Podevels, Angela M; Kevany, Brian M et al. (2009) Biosynthesis of polyketide synthase extender units. Nat Prod Rep 26:90-114
Kevany, Brian M; Rasko, David A; Thomas, Michael G (2009) Characterization of the complete zwittermicin A biosynthesis gene cluster from Bacillus cereus. Appl Environ Microbiol 75:1144-55

Showing the most recent 10 out of 14 publications